<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2004</study_start_year><condition>Colorectal cancer NOS</condition><condition>ADVANCED COLO-RECTAL TUMOUR</condition><disease>Colorectal Cancer Nos</disease><disease>Advanced Colo-rectal Tumour</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2516472</full_dataset_link><location>Italy</location><study_start_month>12</study_start_month><keyword>LEDERFOLIN*EV 1FL LIOF 175MG</keyword><keyword>ERBITUX*INFUS 1FL 50ML 2MG/ML</keyword><keyword>ELOXATIN*IV 1FL POLV 100MG</keyword><keyword>FLUOROURACILE TEVA*IV FL 5G</keyword><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>FOLFOX 4 + CETUXIMAB IN UNTREATED PATIENTS WITH ADVANCED COLO-RECTAL TUMOUR. A PHASE II MULTICENTER STUDY OF THE GRUPPO ONCOLOGICO DELL’ITALIA MERIDIONALE</name><description>Primary objectives: PERCENTAGE OF OBJECTIVE RESPONSES
Primary endpoints: TO ESTIMATE THE PERCENTAGE OF OBJECTIVE RESPONSES</description><dates><creation>2004-12-15</creation></dates><accession>2516472</accession><cross_references><EU Clinical Trials Register>2004-004181-32</EU Clinical Trials Register></cross_references></HashMap>